Answers are grounded in this paper and cite their sources.
Shows Wnt3a's role in reducing TRM function in melanoma, suggesting a pathway for improving immunotherapy outcomes.
TRMs. Finally, transcriptomic analysis of publicly available melanoma cohorts showed that enrichment of the Wnt pathway correlates with poor prognosis and ICB resistance, highlighting this pathway as a potential druggable negative regulator of ICB efficacy in melanoma.
No takes yet. Share an insight, caveat, or question.
Gajón et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: